Back to List View Graph View

Progression-free survival

Progression-free survival (PFS) is the time from the start of treatment until disease progresses or the patient dies of any cause, whichever comes first.

Where the papers sit

12 papers from the last 6 months study progression-free survival directly · updated from PubMed 8 Nov 2026

  • Advanced Cancer Combination Therapies

    Advanced cancers are increasingly treated with combinations pairing targeted agents, chemotherapy, radiotherapy, or hormonal therapy with immune or DNA-repair strategies. In renal cell carcinoma, lenvatinib-based approaches are compared with cabozantinib and checkpoint inhibition, while toripalimab regimens extend combination therapy into other carcinomas. Prostate cancer work combines PARP and androgen-signaling inhibition with ADT, and mismatch-repair–deficient digestive cancers highlight immune-related toxicity. The recurring question is whether deeper disease control justifies added adverse events, with no universal regimen established.

    5 papers · 41.7%

  • Multiple Myeloma Treatment Sequencing

    Frontline daratumumab-based quadruplets are improving disease control over VRd in transplant-eligible multiple myeloma. Later lines increasingly use CAR T-cell therapies and bispecific antibodies, with treatment order becoming a major determinant of long-term survival in relapsed disease. The evidence centers on progression, death, hazard ratios, and follow-up rather than a single preferred sequence. Optimal placement of cellular and bispecific therapies remains open.

    2 papers · 16.7%

  • Others — Cancer Outcomes Across Tumors

    Treatment outcomes range from intensive transplantation for primary CNS lymphoma to radiotherapy for extremity sarcoma and cachexia management in NSCLC. Other work develops PFS nomograms for systemic anaplastic large cell lymphoma or evaluates circulating tumour DNA in nonmetastatic head and neck cancer. The shared focus is prognostication, treatment benefit, and toxicity across malignancies, not one biological mechanism. No common therapeutic direction emerges.

    5 papers · 41.7%

Papers

The 12 papers from the last 6 months that study progression-free survival directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Advanced Cancer Combination Therapies (5)
  1. Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial. Lancet (London, England) · 12 Aug 2026 PMID 42586114
  2. Pembrolizumab Plus Lenvatinib in Metastatic Renal Cell Carcinoma: Real-world Prognostic Factors. Anticancer research · 29 Jul 2026 PMID 42527074
  3. Induction toripalimab plus chemotherapy sequential concurrent chemoradiotherapy with nimotuzumab followed by toripalimab maintenance in stage IVB hypopharyngeal squamous cell carcinoma: a single-arm phase 2 study. Journal for immunotherapy of cancer · 24 Jul 2026 PMID 42498484
  4. Impact on survival of severe immuno-related adverse events in deficient mismatch repair/microsatellite instable-high digestive cancers treated with immunotherapy. Journal for immunotherapy of cancer · 24 Jul 2026 PMID 42498483
  5. PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer. The New England journal of medicine · 1 Jun 2026 PMID 42223064
Multiple Myeloma Treatment Sequencing (2)
  1. Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma. Future oncology (London, England) · 14 Jul 2026 PMID 42444515
  2. Impact of Treatment Sequencing With CAR T-cell Therapies and Bispecific Antibodies on Long-term Survival in 4L+ RRMM in the United States: A Simulation Model. Clinical lymphoma, myeloma & leukemia · 24 Jun 2026 PMID 42342528
Others — Cancer Outcomes Across Tumors (5)
  1. Evaluation of the Clinical Utility of Circulating Tumor DNA in the Management of Patients With Nonmetastatic Head and Neck Cancer: Protocol for a Prospective Bicentric Study (CIRVAD). JMIR research protocols · 5 Nov 2026 PMID 42987275
  2. An individualized nomogram for predicting progression-free survival in systemic anaplastic large cell lymphoma: a multicenter, retrospective, and internally validated study. Hematology (Amsterdam, Netherlands) · 12 Aug 2026 PMID 42584691
  3. Radiotherapy for Soft-tissue Sarcoma of the Extremities: A 10-Year Analysis of Treatment Outcomes and Toxicity at a Large Sarcoma Centre. Anticancer research · 29 Jul 2026 PMID 42527052
  4. High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial. Lancet (London, England) · 22 Jul 2026 PMID 42486133
  5. A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non-Small Cell Lung Cancer With Cachexia (SPIRAL-ANA). Journal of cachexia, sarcopenia and muscle · 7 Jul 2026 PMID 42411631

By study type

Clinical trials (4)
  1. Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial. Lancet (London, England) · 12 Aug 2026 PMID 42586114
  2. Induction toripalimab plus chemotherapy sequential concurrent chemoradiotherapy with nimotuzumab followed by toripalimab maintenance in stage IVB hypopharyngeal squamous cell carcinoma: a single-arm phase 2 study. Journal for immunotherapy of cancer · 24 Jul 2026 PMID 42498484
  3. High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial. Lancet (London, England) · 22 Jul 2026 PMID 42486133
  4. PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer. The New England journal of medicine · 1 Jun 2026 PMID 42223064
Observational studies and case reports (6)
  1. Evaluation of the Clinical Utility of Circulating Tumor DNA in the Management of Patients With Nonmetastatic Head and Neck Cancer: Protocol for a Prospective Bicentric Study (CIRVAD). JMIR research protocols · 5 Nov 2026 PMID 42987275
  2. An individualized nomogram for predicting progression-free survival in systemic anaplastic large cell lymphoma: a multicenter, retrospective, and internally validated study. Hematology (Amsterdam, Netherlands) · 12 Aug 2026 PMID 42584691
  3. Pembrolizumab Plus Lenvatinib in Metastatic Renal Cell Carcinoma: Real-world Prognostic Factors. Anticancer research · 29 Jul 2026 PMID 42527074
  4. Radiotherapy for Soft-tissue Sarcoma of the Extremities: A 10-Year Analysis of Treatment Outcomes and Toxicity at a Large Sarcoma Centre. Anticancer research · 29 Jul 2026 PMID 42527052
  5. Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma. Future oncology (London, England) · 14 Jul 2026 PMID 42444515
  6. A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non-Small Cell Lung Cancer With Cachexia (SPIRAL-ANA). Journal of cachexia, sarcopenia and muscle · 7 Jul 2026 PMID 42411631
Human data, design not indexed (2)
  1. Impact on survival of severe immuno-related adverse events in deficient mismatch repair/microsatellite instable-high digestive cancers treated with immunotherapy. Journal for immunotherapy of cancer · 24 Jul 2026 PMID 42498483
  2. Impact of Treatment Sequencing With CAR T-cell Therapies and Bispecific Antibodies on Long-term Survival in 4L+ RRMM in the United States: A Simulation Model. Clinical lymphoma, myeloma & leukemia · 24 Jun 2026 PMID 42342528